Dextrose News and Research

RSS

Study investigates use of glucose to shorten induced labor in nulliparous woman

In a study to be presented Thursday, Jan. 26, in the oral concurrent session at 1:15 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, researchers with the Université de Sherbrooke in Sherbrooke, Quebec, Canada will present their findings in a study titled, Reduction of total labor length through the addition of parenteral dextrose solution in induction of labor in nulliparous: results of DEXTRONS prospective randomized controlled trial.

23 Jan 2017

Prolotherapy linked to improved knee-specific symptoms in patients with osteoarthritis

Prolotherapy, an injection-based complementary treatment for symptomatic knee osteoarthritis, was associated with improved knee-specific symptoms, quality of life, and ability to participate in daily activities among the majority of individuals who participated in several small clinical studies.

24 Oct 2016

RT with concurrent chemotherapy post surgery is effective for treating endometrial cancer

Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for patients with high-risk endometrial cancer, according to a study published in the September 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

10 Sep 2014

Monarch Medical Technologies gets FDA clearance for new glucose management solution

Monarch Medical Technologies, the pioneer and leader in mitigating risk associated with drugs and processes of concern in hospitalized patients, today announced the U.S. Food and Drug Administration clearance of its new glucose management solution, EndoTool IV.

28 Apr 2014

New nonsurgical approach to treat chronic pain and stiffness linked with knee osteoarthritis

A new nonsurgical approach to treating chronic pain and stiffness associated with knee osteoarthritis has demonstrated significant, lasting improvement in knee pain, function, and stiffness.

9 Apr 2014

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use.

16 Mar 2014

Dextrose gel could treat neonatal hypoglycemia

A cheap and easy-to-administer dextrose gel should be used to treat low blood sugars in newborns (neonatal hypoglycaemia), a common problem that affects up to 15% of otherwise healthy babies, and a preventable cause of brain damage, according to new research published in The Lancet.

27 Sep 2013

Aromatherapy, IV dextrose may relieve nausea and vomiting after surgery

Two simple, non-drug treatments-aromatherapy and intravenous administration of a simple sugar solution-may offer effective new approaches to relieving nausea and vomiting after surgery, report a pair of studies in the September issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

22 Aug 2013

New test hints 3 sodas daily hurt lifespan, reproduction in mice

When mice ate a diet of 25 percent extra sugar - the mouse equivalent of a healthy human diet plus three cans of soda daily - females died at twice the normal rate and males were a quarter less likely to hold territory and reproduce, according to a toxicity test developed at the University of Utah.

14 Aug 2013

New study shows that dietary fructose causes liver damage even without weight gain

The role of dietary fructose in the development of obesity and fatty liver diseases remains controversial, with previous studies indicating that the problems resulted from fructose and a diet too high in calories.

20 Jun 2013

Akorn reports record consolidated revenue of $73.9 million in first quarter 2013

Akorn, Inc., a niche generic pharmaceutical company, today reported financial results for its first quarter ended March 31, 2013.

7 May 2013

FDA approves Arteriocyte’s ACD-A for use with Magellan system

Arteriocyte Medical Systems, Inc. announced today approval by the U.S. Food and Drug Administration (FDA) to manufacture and distribute the Arteriocyte Medical Systems brand of Anticoagulant Citrate Dextrose Solution, USP (ACD-A) for use with its Magellan Platelet Separation System.

5 Jun 2012

Diluent choice affects neuromuscular block times

Anesthesiologists can achieve successful axillary brachial plexus block faster by diluting ropivacaine in dextrose rather than saline, results of a randomized trial show.

30 May 2012

Roundup: Mass. premium increases muted; Iowa cuts payment to charity after fraud probe; Ga. asks EMS providers to save scarce drugs

State regulators on Monday approved third-quarter health insurance rates that will raise premiums an average of just 1.2 percent in the market serving small businesses and individuals, continuing a trend of more modest increases seen over the past three quarters. And several carriers, including Tufts Health Plan of Watertown and Fallon Community Health Plan, based in Worcester, will reduce their rates -- a rarity in Massachusetts health care -- according to data from the state Division of Insurance.

2 May 2012

ACS symposium focuses on biomimetics

Combining the secrets that enable water striders to walk on water and give wood its lightness and great strength has yielded an amazing new material so buoyant that, in everyday terms, a boat made from 1 pound of the substance could carry five kitchen refrigerators, about 1,000 pounds.

27 Mar 2012

Study about impact of drug shortages on U.S. health systems

Increasing drug shortages are impacting patient care and increasing costs to the nation's health system, according to a new study released today by the American Society of Health-System Pharmacists.

13 Jul 2011

B. Braun receives FDA approval to use 1g and 2g Ceftazidime in DUPLEX Drug Delivery System

The U.S. Food and Drug Administration today approved B. Braun Medical Inc.'s application for 1g and 2g Ceftazidime for Injection USP and Dextrose Injection USP in the DUPLEX Drug Delivery System.

From B. Braun Melsungen AG 14 Jun 2011

GE Healthcare announces results of Optison heart ultrasound contrast agent presented at ASE

Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison- (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in improving suboptimal echocardiograms.

14 Jun 2011

New mixed-carb plus protein formulation more effective for female athletes

A "low-carb, mixed-carb" sports drink with added protein leads to prolonged endurance performance in trained female athletes, according to a study in the April issue of The Journal of Strength and Conditioning Research, official research journal of the National Strength and Conditioning Association. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

15 Apr 2011

Insulin could play a new role in fighting Alzheimer's disease: Research

A low dose of insulin has been found to suppress the expression in the blood of four precursor proteins involved in the pathogenesis of Alzheimer's disease, according to new clinical research by University at Buffalo endocrinologists. The research, published in March online in the Journal of Clinical Endocrinology and Metabolism, suggests that insulin could have a powerful, new role to play in fighting Alzheimer's disease.

1 Apr 2011